Extended indication from adults to pediatric patients 5-17 yearsSafety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients < of 5 years have not been establishedPediatric patients treated with PEGASYS plus COPEGUS combination therapy showed a delay in weight and height increases after 48 weeks of therapy compared with baseline. At the end of 2 years follow-up after treatment, most patients returned to baseline normative growth curve percentiles for weight and heightDecreases in hemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment If toxicities occur which may be related to PEGASYS or COPEGUS administration, the dose of one or both can be modifiedAdverse reactions were similar to adultsInformation on dosing, clinical trial, and adverse reactions
|